Bris­tol My­ers Squib­b's just-launched MS drug Zeposia makes the cut in key ul­cer­a­tive col­i­tis tri­al

In March, Zeposia be­came the third oral S1P mod­u­la­tor to se­cure US ap­proval for mul­ti­ple scle­ro­sis. Now, the drug has suc­ceed­ed in a key ul­cer­a­tive col­i­tis study.

The im­munomod­u­la­tor, akin to oth­ers in its class, con­trols lym­pho­cyte traf­fick­ing by lim­it­ing the white blood cells to the lym­phat­ic sys­tem, in the lymph nodes, and thwart­ing their abil­i­ty to jam up lymph nodes — pre­clud­ing their abil­i­ty to pen­e­trate the blood­stream and the cen­tral ner­vous sys­tem.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER